The Blavatnik National Awards were founded in 2007 with the explicit goal of celebrating the potential of scientists at the beginning of their independent careers, a stage of academic life that often lacks the large-scale recognition reserved for senior figures. Each year, the program honors advances in three broad categories: life sciences, chemical sciences, and physical sciences and engineering. From this year’s cohort of 18 finalists, three laureates were selected, each receiving an unrestricted cash prize of $250,000. That figure makes the Blavatnik National Award the largest unrestricted scientific award in the United States for early-career scientists, meaning recipients can direct the money toward whatever research priorities they deem most promising rather than toward a funder-mandated project. Nagib earned the top honor in the chemical sciences category for his work enabling the faster discovery of better and longer-lasting pharmaceuticals.

For Nagib, the recognition is rooted in a research philosophy that has guided his laboratory since he joined Ohio State in 2014. His team develops new ways to create key medicinal building blocks by harnessing two classes of highly reactive chemical species: radicals and carbenes. Radicals are molecules or fragments that carry an unpaired electron, a structural feature that makes them extraordinarily reactive and therefore historically difficult to control in the precise, predictable way that pharmaceutical synthesis demands. Carbenes, meanwhile, are neutral species in which a carbon atom holds only two bonds and a lone pair, giving them the power to insert into other chemical bonds with remarkable efficiency. Both classes of reagents can accomplish transformations that conventional two-electron chemistry struggles to achieve, but taming them has long been a central challenge of synthetic methodology.

The practical motivation behind this work is the notoriously slow pace of pharmaceutical development. On average, it takes 10 to 15 years for a new medicine to travel from initial discovery to the market, a timeline shaped by the difficulty of designing molecules that are potent, selective, stable, and manufacturable at scale. Nagib’s methods attack this bottleneck directly by helping chemists create more potent and selective medicines faster, cheaper, and more efficiently. By giving synthetic chemists reliable new tools for constructing the molecular scaffolds on which drugs are built, his laboratory aims to compress the earliest and often most exploratory stages of the drug development pipeline, where promising candidates are identified and refined before the costly phases of testing and regulatory review begin.

Accessibility is a defining theme of the Nagib group’s approach. Rather than developing techniques that require rare equipment or specialized expertise, the laboratory has pursued chemistry that any researcher could, in principle, carry out. Nagib has described his dream for these advances as chemistry so simple that anyone in the world can do it without specialized techniques or strategies, and he has framed the group’s overarching goal as the democratization of radical chemistry so that it can be used by all, even within artificial intelligence workflows. That ambition reflects a broader shift in synthetic chemistry, where the value of a method is increasingly measured not only by what it can accomplish in an expert’s hands but by how easily it can be adopted, reproduced, and automated across the global research community.

Artificial intelligence has moved from the periphery to the center of that vision. Previously selected as a Blavatnik National Awards finalist in 2024, Nagib has since refocused a substantial portion of his research program on using machine learning to design new catalysts for drug candidates. One outcome of this effort is an open-source database that allows any researcher, even one working from a smartphone, to simulate chemical reactions and learn how to use radicals selectively. The implications of such tools are considerable. According to Nagib, chemical predictions that once would have taken more than a day to complete can now be accomplished in a few seconds, a speedup that changes the practical rhythm of research planning and lets chemists explore far larger regions of chemical space before committing laboratory time and materials to a synthesis.

Despite these dramatic gains in automation and predictive power, Nagib has been careful to emphasize that technology is a complement to human creativity rather than a substitute for it. He has argued that creativity does not come from sitting alone and having a sudden eureka moment, but instead emerges from constantly discussing new ideas, thinking carefully about why they did not pan out, and then coming up with new ones together. In his telling, the most exciting science lives at the edge of the possible, and the perseverance required to make such ideas actually work is the most rewarding part of the discovery process. That collaborative, iterative ethos is visible in the way his laboratory pairs computational prediction with hands-on experimentation, using each to inform and correct the other.

The scale of the competition underscores the significance of the honor. This year, 372 young scientists were nominated for the national awards, representing 187 academic and research institutions across 43 states and the District of Columbia. Finalists are selected by an independent jury of distinguished scientists, a process designed to insulate the evaluation from institutional influence and to reward genuine scientific impact. Since their founding in 2007, the Blavatnik Awards have invested more than $20 million in over 500 scientists worldwide, building a network of laureates and finalists whose work spans disciplines from structural biology to astrophysics. Nagib is being honored on Oct. 6 at the American Museum of Natural History in New York City during the 2026 Blavatnik Awards Gala ceremony, where the winning scientists will each give a short presentation about their research to an audience of peers, patrons, and science leaders.

Looking ahead, Nagib plans to put the monetary award to work immediately within his laboratory, directing the funds toward ongoing projects, the purchase of much-needed equipment and lab instruments, and the pursuit of other new ideas that the prize money makes feasible. Unrestricted awards of this kind are especially valuable for methodological chemistry, where the most speculative projects often struggle to attract conventional grant support before their feasibility is demonstrated. For Ohio State, the laureateship marks a milestone as the university’s first Blavatnik National Award, and for Nagib it serves as a signal from the broader scientific community. As he put it, the award mainly reflects how excited the community is about the work being done at Ohio State, and being recognized in this way motivates the team to keep chasing the stars, a fitting sentiment from a chemist whose career has been built on pursuing the reactive, unruly, and transformative corners of the molecular world.

Subject of Research: Radical and carbene chemistry methods for accelerating pharmaceutical discovery

Article Title: Ohio State professor named Blavatnik National Awards laureate

Article References: Ohio State professor named Blavatnik National Awards laureate. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: David Nagib, Blavatnik National Awards, Ohio State University, radical chemistry, carbenes, medicinal chemistry, drug discovery, artificial intelligence, catalyst design, open-source database, early-career scientists, chemical synthesis

The scale of the competition behind this year’s prizes underscores how coveted the awards have become. The 2026 Laureates were selected from a pool of 372 nominees representing 187 academic and research institutions across 43 states. From that national field, an independent jury of eminent scientists chose three winners and 15 Finalists, each of whom received $15,000 in unrestricted funding. Nine honorees of the Blavatnik Regional Awards were also recognized during the evening. For two institutions the night carried special significance: The Ohio State University and the Arc Institute each celebrated their first-ever Blavatnik National Award Laureate, a milestone that signals how the geography of elite early-career research continues to broaden beyond the usual constellation of coastal institutions.

In the chemical sciences, the Laureate is David Nagib, an organic chemist tackling one of the most persistent bottlenecks in medicine: the sheer difficulty of synthesizing complex molecules. Organic synthesis often determines how quickly a promising drug candidate can be made, tested, and improved, and Nagib’s laboratory has focused on harnessing two of chemistry’s most reactive and unruly species, radicals and carbenes, to forge key medicinal building blocks. Radicals and carbenes are notoriously energetic intermediates, capable of transforming molecules in ways that gentler reagents cannot, but historically difficult to control. Nagib’s group has invented methods to activate portions of complex molecules that were previously considered inert, effectively unlocking chemical real estate that synthetic chemists had long been unable to reach.

The significance of that achievement lies in reliability. By converting high-energy chemistry into dependable, reproducible methods, Nagib’s work allows chemists to create more potent and selective medicines faster, cheaper, and more efficiently than conventional routes permit. In practical terms, that means medicinal chemists can explore a wider swath of chemical space when hunting for new drugs, attaching or rearranging molecular features that were once off-limits. The advances are already accelerating pharmaceutical discovery and expanding the boundaries of what modern organic chemistry can accomplish, a contribution the Blavatnik jury singled out in naming him the Chemical Sciences Laureate.

In the life sciences, the Laureate is Patrick Hsu, a bioengineer and co-founder of the Arc Institute whose work sits at the frontier of genome engineering. Biology depends on molecular machines that read, write, and regulate genetic information, and Hsu’s laboratory discovers and engineers these programmable systems to manipulate DNA and RNA with precision. His contributions have widened the CRISPR toolkit with RNA-targeting enzymes, extending gene-editing capability beyond DNA to the transcriptome. More striking still, his team uncovered programmable bridge RNAs, molecules that can direct large-scale genome rewriting by physically bridging a target DNA site with a donor sequence, a mechanism that hints at edits far more ambitious than the small cuts and swaps of first-generation CRISPR tools.

Hsu has also pushed genome engineering into the age of artificial intelligence, pioneering AI models that predict and design biological sequences. Together, these innovations are transforming how scientists approach genome engineering, accelerating biological discovery, and supporting the development of new gene therapies. The Blavatnik citation describes the work as laying the foundation for a new era of AI-enabled biological design, in which computational models and programmable molecular machines work in tandem to rewrite the instructions of life. The recognition is equally a landmark for the Arc Institute, the young Palo Alto research organization Hsu co-founded, which now counts its first Blavatnik National Award Laureate among its ranks.

The Physical Sciences and Engineering Laureate, Jonathan Rivnay, works on a problem that sounds deceptively simple: the human body runs on chemical and ionic signals, but ordinary electronics struggle to read them, let alone join the conversation. A materials scientist and biomedical engineer, Rivnay designs soft, flexible electronic materials that can interface directly with living cells and tissue, bridging the gap between the wet, ionic world of biology and the electronic world of silicon. His devices must conduct ions as well as electrons, bend without breaking, and operate safely within the body, a set of constraints that has driven much of the field of organic bioelectronics in which he has become a leading figure.

Among Rivnay’s most ambitious contributions are implantable devices he helped pioneer known as living pharmacies. These small implants hold engineered cells and prompt them to manufacture and release medicines inside the body, effectively turning a patient’s own therapeutic cells into a controlled drug factory. The approach points toward more personalized treatments for long-term conditions such as cancer, diabetes, and circadian rhythm disorders, diseases in which dosing needs fluctuate and conventional drugs often fall short. By combining flexible electronics with living cells, Rivnay’s research suggests a future in which therapy is delivered on demand, in place, and in tune with the body’s own signals.

The evening was also an occasion for reflection on what two decades of early-career recognition can produce. Lifton, presenting the awards, traced the trajectory of the inaugural cohort of 14 honorees recognized twenty years earlier. Eight of them now hold named and endowed chairs at institutions including Yale, Rockefeller, Cornell, Columbia, and Cambridge. Five have been elected to the U.S. National Academy of Sciences, two to the National Academy of Medicine, six to the American Academy of Arts and Sciences, and one to the Royal Society of the UK. Subsequent to their Blavatnik Awards, members of that first group have won prizes including the Shaw Prize, the Benjamin Franklin Medal, and the Fields Medal, a record that lends weight to the program’s central bet on identifying talent early.

That bet has a well-documented origin story. Nicholas B. Dirks, President and CEO of The New York Academy of Sciences and Chair of the Awards’ Scientific Advisory Council, recalled in his remarks that the idea was inspired by Len Blavatnik’s experience at the 2007 Nobel Prize ceremony, where the prestige of honoring lifelong discoveries prompted a question: what if exceptional scientists could be recognized earlier in their careers, at a pivotal moment when they were just beginning to build their own research programs, pursue ambitious scientific questions, and take creative risks. The Blavatnik Awards were born as a first-of-its-kind science prize dedicated to the most promising early-career scientists of their generation. Since 2007 the program has honored 539 scientists and awarded $21.5 million in unrestricted funding, and it now spans the United States, the United Kingdom, and Israel, awarding more than $2 million annually. At a time when intense competition for research funding makes it increasingly difficult for young investigators to establish independent programs, unrestricted prize money gives recipients freedom to pursue high-risk, high-reward research that conventional grants often cannot support. The economic ripple effects are tangible as well: Blavatnik honorees to date have founded 52 companies, six of them publicly traded, collectively valued at more than $40 billion, evidence that early recognition of scientific talent can translate into discoveries, therapies, and industries that reach far beyond the laboratory.

Subject of Research: The 2026 Blavatnik Awards for Young Scientists honoring early-career research in organic chemistry, genome engineering and bioelectronics

Article Title: Three scientists honored with $250,000 Blavatnik Awards for breakthroughs in organic chemistry, gene editing and bioelectronics

Article References: Three scientists honored with $250,000 Blavatnik Awards for breakthroughs in organic chemistry, gene editing and bioelectronics. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Blavatnik Awards, David Nagib, Patrick Hsu, Jonathan Rivnay, organic chemistry, CRISPR, bridge RNAs, genome engineering, bioelectronics, living pharmacies, New York Academy of Sciences, early-career scientists